Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFX453 in actinic keratosis
NCT02404389Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Jan 2016
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of LFX453 in actinic keratosis (AK), sponsored by Novartis. Started Mar 2015; status: completed.
02
Drugs
LFX453
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02404389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404389.